Positive Results from the Scandion Oncology A/S and Alligator Bioscience AB Collaboration Further Supports Efficacy of SCO-101 in Combination Therapy
Copenhagen, Denmark, September 2, 2021 – Scandion Oncology (Nasdaq Stockholm: SCOL) and Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced the conclusion of their collaboration with a very positive outcome.The purpose of the collaboration was to explore the anti-tumor efficacy of the CD40 antibody mitazalimab in chemotherapy-resistant preclinical tumor models as an addition to chemotherapy (FOLFIRINOX) combined with SCO-101. The hypothesis that was tested was to see if SCO-101, as compared to saline control will revert chemotherapy resistance and thereby facilitate a